20 Apr, 2012 Positive Clinical Results for ALN-PCS, Reported at ATVB 2012
Posted at 12:08h
in Cardio-Metabolic Disease, Hypercholesterolemia, Presentations, Spotlight, Uncategorized
Yesterday, scientists presented positive results from our Phase I clinical trial of ALN-PCS at the American Heart Association’s Arteriosclerosis, Thrombosis and Vascular Biology 2012 Scientific Sessions held in Chicago. Results showed that administration of a single dose of ALN-PCS, in the absence of concomitant lipid-lowering agents such as statins, resulted in statistically significant and durable reductions of PCSK9 plasma levels of up to 84% and lowering of LDL-C of up to 50%.
The new data also highlight continued improved efficacy and tolerability for Alnylam’s second-generation lipid nanoparticle (LNP) delivery technology.